

Statement of Advice:

opicapone 50mg hard capsules (Ongentys®)
Bial Pharma UK Ltd

SMC No 1281/17

8 September 2017

ADVICE: in the absence of a submission from the holder of the marketing authorisation

opicapone (Ongentys®) is not recommended for use within NHS Scotland.

Indication under review: Adjunctive therapy to preparations of levodopa / DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman
Scottish Medicines Consortium